Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has provided an update.
On October 1, 2025, Quantum BioPharma announced the appointment of Dr. Jack Antel, a world-renowned multiple sclerosis expert, as a clinical development advisor for their Lucid-MS trials. Dr. Antel’s expertise is expected to significantly advance the clinical development of Lucid-MS, a drug designed to inhibit demyelination in multiple sclerosis, potentially enhancing Quantum BioPharma’s positioning in the biopharmaceutical industry.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of drug candidates at various stages, with a key focus on their lead compound, Lucid-MS, aimed at treating multiple sclerosis.
Average Trading Volume: 3,776
Technical Sentiment Signal: Buy
Current Market Cap: C$85.86M
See more insights into QNTM stock on TipRanks’ Stock Analysis page.